Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19
Open Access
- 24 February 2021
- journal article
- research article
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 29 (6) , 340-345
Abstract
Introduction While there are no pharmacological treatments with proven efficacy for coronavirus disease 2019 (COVID-19), tocilizumab has emerged as a candidate therapy. Some aspects of this therapy are still unknown, including the optimal timing of administration. Objective This observational study aimed to compare the 90-day mortality in two cohorts of patients when the drug was administered within the first 10 days from onset of symptoms or after day 11. Methods Patients hospitalised with severe COVID-19 pneumonia who had received tocilizumab were divided into two groups according to when the medication was administered. The primary outcome was 90-day mortality. Secondary outcomes were 30-day mortality, clinical improvement on a 6-item scale by day 6, biomarker improvement by day 6, radiological image improvement by day 10 and SaO2 quotient by day 6. The results in the two groups were compared. Additionally, adverse events relating to tocilizumab were recorded. Results A total of 112 patients were analysed. Both groups were epidemiologically comparable. The results obtained in the primary efficacy variable of the study (90-day mortality) showed a statistically significant difference in the subgroups according to the time of administration of tocilizumab (18.6% vs 5.0%, p=0.048). There was clinical improvement in 24.1% of patients at 6 days, with similar behaviour in both subgroups. No statistically significant differences were found in the percentage of patients who achieved radiological improvement at 10 days or in the other inflammatory parameters, with the exception of significant reductions in lactate dehydrogenase and C-reactive protein. Administration of tocilizumab was not associated with relevant adverse events. Conclusion To our knowledge, this is the first report of data regarding the timing of administration of tocilizumab in patients with COVID-19 pneumonia. A strategy involving tocilizumab administration after 10 days from onset of symptoms may decrease mortality. Further randomised controlled trials are needed to confirm this emerging hypothesis.Keywords
This publication has 25 references indexed in Scilit:
- Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-upeClinicalMedicine, 2020
- Tocilizumab for the treatment of adult patients with severe COVID‐19 pneumonia: A single‐center cohort studyJournal of Medical Virology, 2020
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, ChinaJAMA Internal Medicine, 2020
- Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort studyEuropean Journal of Internal Medicine, 2020
- Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, ItalyAutoimmunity Reviews, 2020
- Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-192020
- Tocilizumab treatment in COVID‐19: A single center experienceJournal of Medical Virology, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell TherapyTransplantation and Cellular Therapy, 2019
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014